Your browser doesn't support javascript.
loading
Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal.
Gomez-Mayordomo, Victor; Montero-Escribano, Paloma; Matías-Guiu, Jordi A; González-García, Nuria; Porta-Etessam, Jesús; Matías-Guiu, Jorge.
Afiliação
  • Gomez-Mayordomo V; Department of Neurology, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Hospital Clínico San Carlos, Universidad Complutense, Madrid, Spain.
  • Montero-Escribano P; Department of Neurology, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Hospital Clínico San Carlos, Universidad Complutense, Madrid, Spain.
  • Matías-Guiu JA; Department of Neurology, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Hospital Clínico San Carlos, Universidad Complutense, Madrid, Spain.
  • González-García N; Department of Neurology, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Hospital Clínico San Carlos, Universidad Complutense, Madrid, Spain.
  • Porta-Etessam J; Department of Neurology, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Hospital Clínico San Carlos, Universidad Complutense, Madrid, Spain.
  • Matías-Guiu J; Department of Neurology, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Hospital Clínico San Carlos, Universidad Complutense, Madrid, Spain.
J Med Virol ; 93(1): 546-549, 2021 01.
Article em En | MEDLINE | ID: mdl-32644205
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Cloridrato de Fingolimode / SARS-CoV-2 / COVID-19 / Imunossupressores Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Cloridrato de Fingolimode / SARS-CoV-2 / COVID-19 / Imunossupressores Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article